471 related articles for article (PubMed ID: 29265356)
21. Quantitation of minimal residual disease in multiple myeloma using an allele-specific real-time PCR assay.
Rasmussen T; Poulsen TS; Honoré L; Johnsen HE
Exp Hematol; 2000 Sep; 28(9):1039-45. PubMed ID: 11008016
[TBL] [Abstract][Full Text] [Related]
22. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders.
Ladetto M; Brüggemann M; Monitillo L; Ferrero S; Pepin F; Drandi D; Barbero D; Palumbo A; Passera R; Boccadoro M; Ritgen M; Gökbuget N; Zheng J; Carlton V; Trautmann H; Faham M; Pott C
Leukemia; 2014 Jun; 28(6):1299-307. PubMed ID: 24342950
[TBL] [Abstract][Full Text] [Related]
23. [Methods and clinical values for minimal residual disease detection in patients with multiple myeloma].
Takamatsu H
Rinsho Ketsueki; 2018; 59(10):2153-2161. PubMed ID: 30305521
[TBL] [Abstract][Full Text] [Related]
24. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia.
Nunes V; Cazzaniga G; Biondi A
Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364
[TBL] [Abstract][Full Text] [Related]
25. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
26. Quantitative polymerase chain reaction analysis with allele-specific oligonucleotide primers for individual IgH VDJ regions to evaluate tumor burden in myeloma patients.
Sata H; Shibayama H; Maeda I; Habuchi Y; Nakatani E; Fukushima K; Fujita J; Ezoe S; Tadokoro S; Maeda T; Mizuki M; Kosugi S; Nakagawa M; Ueda S; Iida M; Tokumine Y; Azenishi Y; Mitsui H; Oritani K; Kanakura Y
Exp Hematol; 2015 May; 43(5):374-381.e2. PubMed ID: 25591497
[TBL] [Abstract][Full Text] [Related]
27. High applicability of ASO-RQPCR for detection of minimal residual disease in multiple myeloma by entirely patient-specific primers/probes.
Bai Y; Wong KY; Fung TK; Chim CS
J Hematol Oncol; 2016 Oct; 9(1):107. PubMed ID: 27724958
[TBL] [Abstract][Full Text] [Related]
28. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
Yu Q; Shi JM; Tao Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
[TBL] [Abstract][Full Text] [Related]
29. Minimal residual disease testing after stem cell transplantation for multiple myeloma.
Sherrod AM; Hari P; Mosse CA; Walker RC; Cornell RF
Bone Marrow Transplant; 2016 Jan; 51(1):2-12. PubMed ID: 26191950
[TBL] [Abstract][Full Text] [Related]
30. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
[TBL] [Abstract][Full Text] [Related]
31. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
[TBL] [Abstract][Full Text] [Related]
32. Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma.
Hultcrantz M; Rustad EH; Yellapantula V; Jacob A; Akhlaghi T; Korde N; Mailankody S; Lesokhin AM; Hassoun H; Smith EL; Lahoud OB; Landau HJ; Shah GL; Scordo M; Chung DJ; Giralt S; Papaemmanuil E; Landgren O
Clin Cancer Res; 2022 May; 28(10):2160-2166. PubMed ID: 35553646
[TBL] [Abstract][Full Text] [Related]
33. Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides.
Takamatsu H; Ogawa Y; Kobayashi N; Obata K; Narisawa T; Nakayama K; Munemoto S; Aoki G; Ohata K; Kumano Y; Ozaki J; Murata R; Kondo Y; Terasaki Y; Kurokawa T; Miyamoto T; Shimizu N; Fukushima T; Yoshida A; Ueda T; Yoshida T; Nakao S
Exp Hematol; 2013 Oct; 41(10):894-902. PubMed ID: 23727584
[TBL] [Abstract][Full Text] [Related]
34. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
Bal S; Weaver A; Cornell RF; Costa LJ
Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
[TBL] [Abstract][Full Text] [Related]
35. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
[TBL] [Abstract][Full Text] [Related]
36. Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.
Korthals M; Sehnke N; Kronenwett R; Schroeder T; Strapatsas T; Kobbe G; Haas R; Fenk R
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1109-15. PubMed ID: 23644045
[TBL] [Abstract][Full Text] [Related]
37. A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.
Takamatsu H; Wee RK; Zaimoku Y; Murata R; Zheng J; Moorhead M; Carlton VEH; Kong KA; Takezako N; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Br J Haematol; 2018 Nov; 183(4):664-668. PubMed ID: 29270982
[No Abstract] [Full Text] [Related]
38. Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma.
Yao Q; Bai Y; Orfao A; Chim CS
Front Oncol; 2019; 9():449. PubMed ID: 31245284
[TBL] [Abstract][Full Text] [Related]
39. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
Bal S; Costa LJ
Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
[TBL] [Abstract][Full Text] [Related]
40. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
